Wealth Alliance Reduces Holdings in Sanofi (NASDAQ:SNY)

Wealth Alliance trimmed its stake in Sanofi (NASDAQ:SNY) by 6.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,320 shares of the company’s stock after selling 2,037 shares during the period. Wealth Alliance’s holdings in Sanofi were worth $1,414,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in Sanofi by 434.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 50,583 shares of the company’s stock worth $2,915,000 after purchasing an additional 41,117 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in Sanofi during the 3rd quarter worth $29,000. Foundations Investment Advisors LLC purchased a new position in Sanofi during the 3rd quarter worth $248,000. Signaturefd LLC grew its position in Sanofi by 7.6% during the 3rd quarter. Signaturefd LLC now owns 37,347 shares of the company’s stock worth $2,152,000 after purchasing an additional 2,647 shares during the last quarter. Finally, Symphony Financial Ltd. Co. purchased a new position in Sanofi during the 3rd quarter worth $207,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.6 %

SNY stock opened at $53.60 on Thursday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a market capitalization of $136.03 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a fifty day moving average of $50.65 and a 200-day moving average of $52.49.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.